NanoViricides Inc (NYSE: NNVC) has filed an application with the local regulatory agency ACOREP to initiate a Phase II clinical trial of its NV-387 Oral Gummies. The proposed study aims to treat the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of Congo (DRC). This filing marks a critical step for the clinical-stage antiviral developer, which stated it is eagerly awaiting regulatory approval to commence the trial. The company confirmed that it has already raised the necessary financing to support the execution of this clinical program.

Trial Details and Regulatory Status

The application submitted to ACOREP seeks permission to evaluate NV-387 Oral Gummies specifically as a treatment for the Bundibugyo strain of the Ebolavirus. NanoViricides described itself as a leader developing antiviral drugs that viruses cannot escape, positioning NV-387 as a potential therapeutic intervention for the ongoing outbreak in the DRC.

Key details of the filing include:

Financial Readiness

NanoViricides emphasized that financial constraints will not delay the potential start of the trial, noting that it has already secured the funding required to support the clinical operations. This pre-funding strategy suggests the company is prepared to mobilize resources immediately upon receiving regulatory clearance from ACOREP.

What the Numbers Show

While no specific financial figures were disclosed in the announcement, the confirmation of secured financing indicates capital preservation or successful fundraising prior to this regulatory milestone. For a clinical-stage company, having funds in place before regulatory approval reduces execution risk and allows for faster trial initiation compared to peers who may need to raise capital post-approval.

NanoViricides has shipped NV-387 oral gummies to the Democratic Republic of Congo (DRC) to prepare for patient enrollment in its Phase II clinical trial for Monkeypox treatment. The shipment enables the initiation of the study, which aims to evaluate the safety and effectiveness of the oral formulation against the hMPXV infection. Patient enrollment and dosing are expected to commence once staff training is completed in a few weeks.

Clinical trial site preparations are being conducted by Om Sai Clinical Research Pvt. Ltd., the company's contract research organization in India, along with associates in DRC. Despite travel restrictions, changing flight schedules, and cancellations, CRO personnel have visited the site multiple times to ensure readiness. The trial had previously faced delays due to a change in the clinical trial site away from Kinshasa, as the new location required substantial preparation to meet necessary standards.

An on-site examination by the CRO revealed that the new site needed significant upgrades. Additionally, preparations were hindered by travel restrictions within DRC and internationally, imposed following the May 17 declaration of a Public Health Emergency of International Concern (PHEIC) due to an Ebola outbreak in DRC. NanoViricides believes NV-387 could be a useful treatment for the current Ebola Bundibugyo Virus outbreak.

The company has received approval from the Regulatory Agency ACOREP of DRC to start the Phase II clinical trial. The study will focus on MPox Clade I, which is endemic in DRC and is considered more severe than MPox Clade II. NanoViricides has applied to the US FDA for Orphan Drug Designation for NV-387 for the treatment of MPox.

NV-387 is a broad-spectrum antiviral drug candidate designed to mimic human cells to trap and destroy viruses. The company believes this host-mimetic mechanism makes viral escape highly unlikely. NanoViricides is also developing NV-387 as a treatment for other viral infections, including RSV, COVID, and Influenza.

Key Developments